Catalent

KYCO: Know Your Company

Reveal Profile

28 October 2025

1) Overview of the Service Provider

Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission centers on developing, manufacturing, and supplying products that help people live better and healthier lives. The company operates as the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients worldwide.

Catalent provides comprehensive services across multiple therapeutic modalities through two primary operating segments: Biologics and Pharma and Consumer Health. The Biologics segment encompasses formulation, development, and manufacturing for biologic proteins, cell and gene therapies, plasmid DNA, vaccines, and analytical services for large molecules. The Pharma and Consumer Health segment offers capabilities for oral solid dose forms, softgels, Zydis fast-dissolve technologies, clinical supply services, and consumer health products.

The company maintains a substantial global footprint with over 50 manufacturing and development sites across four continents, enabling it to supply nearly 70 billion doses of approximately 8,000 products annually. Catalent’s expert workforce comprises approximately 17,000 employees, including more than 3,000 scientists and technicians. The company generated approximately $4.4 billion in revenue during its 2024 fiscal year.

Catalent serves over 1,000 customers across pharmaceutical, biotechnology, and consumer health industries, ranging from small virtual organizations to large multinational corporations. Major clients include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Novo Nordisk, Moderna, Pfizer, and Sarepta Therapeutics. The company has supported more than half of the products approved by the FDA in the last ten years and helps accelerate over 1,500 partner development programs while launching over 150 new products annually.

Within the competitive landscape, Catalent competes with major CDMOs including Thermo Fisher Scientific, Lonza Group, WuXi Biologics, and Charles River Laboratories. The company differentiates itself through proprietary technologies such as GPEx cell line development, SMARTag antibody-drug conjugate platform, Zydis fast-dissolve tablets, and OptiForm solution suites. In December 2024, Novo Holdings A/S completed the acquisition of Catalent for approximately $16.5 billion, transitioning the company to private ownership while maintaining its independent CDMO operations.

2) History

Catalent, Inc. traces its origins to the innovative work of Robert Pauli Scherer, who in 1930 invented the revolutionary “rotary die” process for softgel encapsulation from his Detroit basement. This breakthrough transformed softgel production from a manual method to a commercial, high-volume process, with Scherer receiving his patent in 1933 and earning 52 additional patents before his death in 1960. The experimental machine was later placed in the Smithsonian Institution in Washington D.C. in 1955, recognizing its significance to pharmaceutical manufacturing.

The company’s modern structure emerged through Cardinal Health’s strategic acquisitions beginning in the 1990s. Cardinal Health acquired PCI Services in 1996, followed by R.P. Scherer Corporation for $2.2 billion in 1998, establishing the foundation of what would become Catalent. Subsequent acquisitions included Automatic Liquid Packaging in 1999 for blow-fill-seal technology, International Processing Corporation in 2001 for $40 million, Magellan Laboratories in 2002 for analytical services, and Intercare Group PLC in 2003 for $530 million to expand European capabilities.

On April 10, 2007, Catalent was formed when The Blackstone Group acquired Cardinal Health’s Pharmaceutical Technologies and Services segment, rebranding it as Catalent Pharma Solutions. The name “Catalent” was chosen to reflect the company’s role as a catalyst in accelerating clients’ products to market while highlighting its inherent talent in drug development and manufacturing.

Following its independence, Catalent pursued aggressive expansion and technology acquisition strategies. In 2011, the company acquired a majority stake in Redwood Bioscience, gaining access to SMARTag technology for developing antibody-drug conjugates. The company completed its initial public offering in July 2014, raising approximately $870 million and began trading on the New York Stock Exchange under ticker symbol CTLT.

Major strategic acquisitions followed, including Micron Technologies in 2014 for particle engineering capabilities, Pharmatek Laboratories in 2016 for spray drying technologies, and Cook Pharmica for $950 million in 2017, significantly expanding biologics manufacturing capabilities. In 2019, Catalent acquired Paragon Bioservices for $1.2 billion to strengthen its gene therapy manufacturing position, followed by MaSTherCell for $315 million in 2020 for cell therapy capabilities.

The COVID-19 pandemic marked a pivotal period, with Catalent partnering with multiple drugmakers including Pfizer, Johnson & Johnson, AstraZeneca, and Moderna to provide manufacturing, vial filling, and packaging capabilities for vaccine candidates. In 2021, the company acquired Bettera Holdings for $1 billion to expand into nutritional supplements, and in 2022 acquired Metrics Contract Services for $475 million to enhance oral dosage form capabilities.

Organizational restructuring occurred in July 2022 when Catalent consolidated from four reporting segments to two: Biologics and Pharma and Consumer Health, each representing roughly half of total company revenue. Alessandro Maselli became President and CEO on July 1, 2022, succeeding John Chiminski who transitioned to Executive Chair.

In February 2024, Catalent announced its pending acquisition by Novo Holdings A/S for $16.5 billion, with the transaction completing in December 2024. As part of the deal, Novo Nordisk acquired three fill-finish manufacturing sites from Novo Holdings for $11 billion to support production of diabetes and obesity medications. The company relocated its global headquarters from Somerset, New Jersey to Tampa, Florida in September 2025, while maintaining a corporate office in Bridgewater, New Jersey.

3) Key Executives

Alessandro Maselli serves as President and Chief Executive Officer of Catalent since July 2022. Maselli previously held the position of President and Chief Operating Officer from February 2019 to July 2022, joining Catalent in 2010 as Director of Operations at the company’s pharmaceutical, nutritional, and cosmetics facility in Aprilia, Italy. He holds a master’s degree in engineering from the University of Rome and began his career as an automation systems engineer in the food industry, subsequently holding operational and business leadership roles at Alstom, SGS, and ABB.

Matti Masanovich was appointed Senior Vice President and Chief Financial Officer in July 2023. His responsibilities encompass all aspects of Catalent’s global financial operations, including financial planning and analysis, controllership, public reporting and investor relations, capital markets activities, bill payment and collection, tax, and treasury. Previously, he served as Executive Vice President and Chief Financial Officer of Tenneco Automotive until its acquisition by Apollo, and formerly held CFO positions at Superior Industries International and General Cable Corporation. Masanovich began his career with PricewaterhouseCoopers LLP and holds Bachelor of Commerce and MBA degrees from the University of Windsor, along with Chartered Accountant certification in Canada.

Joseph A. Ferraro serves as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary since February 2023. He is responsible for managing Catalent’s global legal and compliance operations and serves on the Executive Leadership Team. Prior to joining Catalent, Ferraro served as Chief Legal Officer and Secretary for Innovate Corp., managing global legal and compliance operations for a publicly traded, diversified holding company. He holds a Juris Doctor degree with honors from The Law School at the University of Chicago, where he served as managing editor of the University of Chicago Law Review, and a Bachelor of Arts cum laude in public and international affairs from Princeton University.

Lisa Evoli was named Senior Vice President and Chief Human Resources Officer, joining Catalent from Integra Lifesciences. She brings more than 25 years of experience in organizational results, talent pipeline development, and creating inclusive workforces for multinational public companies. Prior to Integra Lifesciences, Evoli held senior leadership roles at TE Connectivity, Johnson & Johnson, and Motorola. She holds a bachelor’s degree in business administration from California University of Pennsylvania and a master’s degree in human resources development from Villanova University.

Scott Gunther serves as Senior Vice President, Quality & Regulatory Affairs. Gunther has been serving in General Counsel capacity since April 2017 according to available records.

Ricky Hopson holds the position of Group President, Clinical and Specialty Services, and Chief of Staff. In this role, Hopson oversees the company’s clinical development and supply operations while serving as Chief of Staff to the executive leadership team.

Charles Lickfold serves as Senior Vice President and Chief Technology Officer, having been promoted to this position in December 2024. He initially joined Catalent in 2020 as Senior Vice President and Chief Information Officer. Prior to joining Catalent, Lickfold held numerous IT leadership positions, including Chief Information Officer roles at Alcami Corp., Avara Pharmaceutical Services, and Gilbarco-Veeder-Root, and served as Vice President and Head of IT for Patheon. He earned a bachelor’s degree in computer science from the University of Kentucky’s College of Engineering and began his career as a management consultant in the life sciences practice of Ernst & Young LLP.

David McErlane serves as Group President, Biologics, overseeing the company’s biologics segment operations. The Biologics segment encompasses formulation, development, and manufacturing for biologic proteins, cell and gene therapies, plasmid DNA, vaccines, and analytical services for large molecules.

4) Ownership

Catalent, Inc. transitioned from public to private ownership in December 2024 following the completion of a transformative $16.5 billion acquisition by Novo Holdings A/S. Under the terms of the merger agreement executed in February 2024, Novo Holdings acquired all outstanding shares of Catalent for $63.50 per share in cash, representing a premium of approximately 47.5% to the 60-day volume-weighted average price as of February 2, 2024. The transaction marked the end of Catalent’s decade-long presence as a publicly traded company on the New York Stock Exchange under ticker symbol CTLT.

Novo Holdings A/S serves as Catalent’s new parent company and operates as a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S, while managing an investment portfolio with a long-term return perspective. As of year-end 2023, Novo Holdings maintained total assets of EUR 149 billion and operates as a world-leading life sciences investor through its Seed, Venture, Growth, Asia, Planetary Health, and Principal Investments teams.

The acquisition structure included a strategic divestiture component whereby Novo Nordisk A/S acquired three of Catalent’s fill-finish manufacturing sites from Novo Holdings shortly following the transaction completion. These facilities, located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium, along with related assets, were transferred to support Novo Nordisk’s production capacity requirements for diabetes and obesity medications.

Prior to the acquisition, Catalent operated as a publicly traded company since its initial public offering in July 2014, when it raised approximately $870 million and began trading on the New York Stock Exchange. The company’s previous ownership structure included The Blackstone Group as a significant shareholder, having acquired the company’s predecessor from Cardinal Health’s Pharmaceutical Technologies and Services segment in 2007. Following the December 2024 acquisition completion, Catalent’s common stock ceased trading and was delisted from the New York Stock Exchange, with shareholders receiving the agreed-upon cash consideration.

The transaction was structured to maintain Catalent’s operational independence as a leading global contract development and manufacturing organization under Novo Holdings’ ownership. Alessandro Maselli continued as President and Chief Executive Officer following the acquisition, with the company positioned to leverage Novo Holdings’ resources and life sciences expertise to enhance its service offerings and accelerate growth initiatives.

5) Legal Claims and Actions

Catalent, Inc. and its subsidiaries have faced various legal proceedings ranging from employment matters to trade secrets violations and regulatory compliance issues. The most recent significant legal action occurred in July 2025 when Catalent Pharma Solutions, LLC filed a complaint against former employee Ben Woodard for alleged violations of the Defend Trade Secrets Act. The case involves allegations that Woodard forwarded confidential company information to his personal email, downloaded over 300 confidential files after his termination, and threatened to disclose proprietary information globally unless his severance demands were met. The court granted a temporary restraining order preventing Woodard from accessing, using, or disclosing Catalent’s confidential information, with the company required to post a $10,000 bond.

In April 2025, Catalent Pharma Solutions LLC faced a Fair Labor Standards Act lawsuit filed by Kearby et al. in the New Jersey District Court. Additionally, in June 2025, the company was named as defendant in an employment discrimination case filed in the Missouri Western District Court, which was removed from state court and involved allegations under Title VII of the Civil Rights Act.

In September 2024, Catalent Pharma Solutions, LLC was sued by Jon Michael Tyson for personal injury in the U.S. District Court for the Western District of Missouri, with a jury trial scheduled for October 2025. The company successfully obtained a favorable arbitration award of $4,512,482.63 plus interest in February 2025 against Romark Global Pharma, LLC in a breach of contract dispute involving pharmaceutical product manufacturing and contamination issues.

Patent infringement litigation remains ongoing from November 2021, when UCB, Inc. and related entities alleged that Catalent Pharma Solutions, Inc., Catalent Pharma Solutions, LLC, and Catalent, Inc. infringed their patent for the compound lacosamide by importing the substance into the United States. The court denied Catalent’s motion to dismiss, finding that UCB stated a plausible claim for patent infringement based on allegations that Catalent caused another corporation to import over 550 kilograms of lacosamide between April 2019 and September 2020.

Several employment-related matters have been resolved favorably for Catalent. In 2024, the company successfully defended against Family Medical Leave Act claims filed by Terry Wood, with the case dismissed with prejudice and each party bearing their own costs. Similarly, in 2018, Catalent obtained summary judgment in a religious and disability discrimination case filed by former employee Logan Ray under Title VII and the Americans with Disabilities Act. An earlier Family Medical Leave Act case from 2018 was also dismissed with prejudice with no penalties incurred.

The company faced a fraud complaint in 2010 when Catalent Pharma Solutions, LLC filed against Stephan Thomas Narewski, II and Mark Odessa in the Eastern District of Pennsylvania, though the case was later consolidated with other related matters. Additionally, subsidiary Paragon Bioservices, Inc. restated prior period financial statements in 2017 to correct errors in historical accounting for capital leases.

Regulatory compliance issues emerged in 2008 when the FDA issued a warning letter to Catalent Pharma Solutions following an inspection that documented deviations from current good manufacturing practices. The violations included failures in quality control investigations, contamination prevention procedures, analytical method validation, and establishment of appropriate specifications and testing procedures. The FDA warned that failure to promptly correct these deviations could result in regulatory action including seizure and/or injunction.

6) Recent Media Coverage

Catalent, Inc.’s media coverage from 2023 to 2025 has been dominated by its acquisition by Novo Holdings, persistent manufacturing compliance issues, financial underperformance, and significant corporate restructuring, including management changes and layoffs. In December 2024, Novo Holdings completed its $16.5 billion all-cash acquisition of Catalent, taking the company private and leading to its delisting from the New York Stock Exchange and the S&P 500. The deal, which included the subsequent sale of three of Catalent’s key fill-finish facilities in Indiana, Italy, and Belgium to Novo Nordisk, faced considerable scrutiny from lawmakers and competitors over antitrust concerns. The transaction received clearance from European regulators in December 2024 and proceeded after the U.S. Federal Trade Commission (FTC), which had requested additional information in May 2024, did not challenge the deal.

Throughout this period, Catalent has been subject to intense regulatory scrutiny over its manufacturing operations, particularly at the Bloomington, Indiana plant, which was part of the sale to Novo Nordisk. Following an October-November 2023 inspection that found quality control lapses, including the discovery of a “pest” on a manufacturing line and inadequate procedures to prevent contamination, the FDA issued a Form 483. In August 2025, the facility received another Form 483 for infringements including the improper investigation of contaminants like cat and human hair and the failure to assess the impact of a bacterial incursion. These issues were linked to regulatory delays for client Regeneron’s Eylea HD drug. By October 2025, the FDA had designated the Bloomington plant’s compliance status as “Official Action Required,” a serious classification indicating an unacceptable state that could further delay drug approvals for its customers. Similar sterile-safety failures were reported at the company’s Brussels plant in 2023, which had previously impacted the supply of Novo Nordisk’s Wegovy.

These operational challenges have been linked to significant financial and organizational turmoil. In April 2023, Catalent disclosed productivity issues and higher costs at its Harmans, Bloomington, and Brussels sites, which contributed to a lowered profit forecast in May 2023 and a stock price decline. The company reported a net loss of $715 million for the first quarter of fiscal 2024, driven primarily by a $700 million goodwill impairment charge, and delayed its quarterly filing. For the full 2023 fiscal year, Catalent reported a revenue decline of $539 million and the termination of 1,100 employees. Further restructuring in late 2023 involved approximately 300 more job cuts and the closure of its San Francisco facility. Layoffs continued into 2024 and 2025, with about 130 positions cut at the Bloomington plant in March 2024 and another 350 in its Maryland-based gene therapy division in August 2025, attributed to an unexpected drop in demand from a large customer.

The company’s performance and disclosures have prompted legal action from investors. A shareholder class-action lawsuit was filed in February 2023, alleging the company misled investors by overstating revenue, misrepresenting product demand, and concealing quality control failures and GAAP violations following the decline in COVID-19-related work. In June 2024, a federal court largely denied Catalent’s motion to dismiss, allowing the case to proceed on narrowed claims related to quality control, facility conditions, and GAAP compliance. Separately, a shareholder derivative suit filed in August 2023 accused executives and board members of similar misrepresentations regarding production and finances. In early 2025, Catalent also sold its oral solids manufacturing facility in Somerset, New Jersey to Ardena as part of its ongoing strategic changes.

Catalent experienced significant leadership turnover, beginning with a major executive and operational restructuring in July 2022 that saw Alessandro Maselli become CEO. In August 2023, the company reached a settlement with activist investor Elliott Investment Management, resulting in a strategic review and the appointment of four new directors, including Elliott executive Steven Barg, with John Greisch becoming Executive Chairman. Following the Novo Holdings acquisition, three new directors were appointed to the board in February 2025 to complete its updates.

7) Strengths

Advanced Technology Portfolio and Innovation Leadership

Catalent maintains an industry-leading portfolio of proprietary technologies that provide significant competitive advantages in drug development and manufacturing. The company’s innovative platforms include Zydis fast-dissolve tablets, which dissolve in approximately three seconds without water and are used in over 35 drugs approved in 60 countries. The GPEx cell line development technology has been utilized in over 50 clinical trials and 10 commercially approved products, enabling rapid creation of high-yielding cell lines for biologics manufacturing. The SMARTag bioconjugation platform enables site-specific, controlled drug-protein conjugations for antibody-drug conjugates, representing cutting-edge advancement in targeted therapeutics. Additional proprietary technologies include OptiForm Solution Suite for bioavailability enhancement, OptiGel Lock abuse-deterrent technology, and RP Scherer softgel technology that revolutionized capsule manufacturing through the rotary die process.

Global Scale and Manufacturing Excellence

Catalent operates an extensive global manufacturing network comprising more than 50 facilities across four continents, providing unparalleled scale and geographic reach. The company supplies nearly 70 billion doses of approximately 8,000 products annually to over 1,000 customers worldwide, demonstrating exceptional manufacturing capacity and operational excellence. This global footprint includes FDA, EMA, and other internationally-approved facilities that enable flexible manufacturing at appropriate scales for both clinical and commercial needs. Catalent’s manufacturing capabilities span multiple modalities including oral solid dosage forms, biologics, gene therapies, and specialized delivery systems, with dedicated suites for highly potent compounds and controlled substances. The Winchester, Kentucky facility alone produces over three billion tablets and capsules annually, exemplifying the company’s large-scale production capabilities.

Comprehensive Service Integration and End-to-End Solutions

Catalent provides uniquely integrated services spanning the entire drug development lifecycle from preclinical formulation through commercial manufacturing and supply. The company’s comprehensive offerings include development sciences, analytical services, clinical supply management, regulatory support, and commercial packaging across multiple therapeutic modalities. This integration enables seamless technology transfers, reduces development timelines, and eliminates coordination challenges associated with multiple vendors. Catalent’s OptiForm Total Supply solution exemplifies this integrated approach, combining development, manufacturing, and clinical supply services to accelerate time to clinic. The company’s clinical supply network includes nine facilities and over 50 strategically located depots across six continents, supporting global clinical trials with specialized packaging, cold chain logistics, and direct-to-patient services.

Deep Scientific Expertise and Proven Track Record

Catalent employs approximately 17,000 professionals including more than 3,000 scientists and technicians, representing one of the industry’s largest concentrations of specialized pharmaceutical expertise. The company has supported more than half of FDA new drug approvals in the last ten years and accelerates over 1,500 partner development programs annually. With over 85 years of drug development experience, Catalent has worked with over 50 new molecular entity approvals since 2004, demonstrating deep formulation expertise for complex molecules. The company’s scientific capabilities encompass advanced formulation development, particle engineering, analytical chemistry, bioavailability enhancement, and specialized manufacturing for novel therapeutic modalities including cell and gene therapies.

Strong Customer Relationships and Market Position

Catalent serves major pharmaceutical and biotechnology companies including Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Novo Nordisk, Moderna, and Pfizer, reflecting strong industry relationships and customer confidence. The company’s customer base spans from small virtual organizations to large multinational corporations, with scalable approaches tailored to specific program requirements. Catalent launches over 150 new products annually for customers and maintains over 1,000 active development programs at any given time, indicating robust business momentum and customer demand. The company’s patient-first culture and commitment to quality excellence supports long-term customer partnerships and positions Catalent as a trusted strategic development partner rather than a transactional supplier.

Quality Systems and Regulatory Excellence

Catalent maintains comprehensive Quality Management Systems that are ISO14001-certified for environmental management and OHSAS18001-certified for occupational safety, with global accreditation from the British Standards Institute. The company’s quality systems comply with FDA, EMA, and other international regulatory requirements across its global network, with facilities approved by 35 regulatory agencies. Catalent prepares over 150 regulatory agency submissions annually and maintains expertise across diverse therapeutic areas and project types, from small to large molecules. The company’s quality assurance approach includes dedicated internal audit teams, standardized operating procedures, and proactive regulatory intelligence monitoring to ensure inspection readiness across all facilities. Catalent’s robust quality culture emphasizes patient-first principles and continuous improvement, supporting regulatory compliance and customer confidence.

8) Potential Risks and Areas for Further Due Diligence

Persistent Manufacturing Quality Control Deficiencies

Catalent has demonstrated recurring quality control failures across multiple critical manufacturing facilities that warrant significant investor scrutiny. The FDA designated the Bloomington, Indiana facility with “Official Action Required” status in October 2025, indicating an unacceptable compliance state that could delay drug approvals for customers. Multiple FDA Form 483 inspections between 2022 and 2025 documented systematic quality control lapses, including the discovery of contaminants such as cat and human hair, bacterial incursions, and inadequate contamination prevention procedures. The company recorded approximately 194 deviations between October 2021 and October 2023 at the Bloomington facility alone, with Catalent failing to identify root causes for 171 of these incidents. Similar sterile-safety failures at the Brussels facility have previously impacted supply of major client products, highlighting systemic quality management challenges across the global network.

Significant Financial Performance Volatility and Losses

Catalent’s financial performance has exhibited substantial volatility, with the company reporting a net loss of $715 million in the first quarter of fiscal 2024, driven primarily by a $700 million goodwill impairment charge. The company experienced revenue declines of $539 million in fiscal 2023 and implemented workforce reductions totaling over 1,100 employees, followed by additional layoffs of approximately 480 positions through 2025. These financial challenges coincided with productivity issues at three major facilities that prevented the company from achieving anticipated revenue levels and profitability targets. The combination of operational difficulties and financial underperformance raises questions about management’s ability to maintain consistent service delivery and operational excellence during periods of stress.

Regulatory Compliance and FDA Oversight Risks

The company faces heightened regulatory scrutiny with ongoing FDA compliance issues that could impact customer relationships and business continuity. Beyond the quality control violations, Catalent received an FDA warning letter in 2008 for deviations from current good manufacturing practices, indicating a pattern of regulatory challenges spanning multiple years. The company operates in a highly regulated environment where FDA inspections occur more than 50 times annually across its global network, creating continuous exposure to potential compliance violations that could result in facility shutdowns or customer disruptions. The designation of facilities with “Official Action Required” status represents serious regulatory concerns that could escalate to enforcement actions including seizure or injunction.

Leadership Stability and Corporate Governance Concerns

Catalent has experienced significant leadership turnover and corporate governance changes that may impact operational continuity and strategic direction. The company underwent major executive restructuring in July 2022, reached a settlement with activist investor Elliott Investment Management in August 2023 that resulted in four new board appointments, and faced the departure of key executives including the CFO. Following the December 2024 acquisition by Novo Holdings, the company appointed three additional new directors in February 2025, representing substantial board composition changes within a compressed timeframe. This pattern of leadership instability, combined with activist investor intervention and ownership transition, creates uncertainty regarding strategic consistency and management continuity.

Trade Secrets Protection and Information Security Vulnerabilities

Recent legal proceedings reveal potential weaknesses in Catalent’s protection of confidential information and trade secrets. In July 2025, the company filed a lawsuit against former employee Ben Woodard under the Defend Trade Secrets Act, alleging that he forwarded confidential information to his personal email, downloaded over 300 confidential files, and threatened to disclose proprietary information globally unless severance demands were met. The case highlights vulnerabilities in the company’s information security protocols and suggests that sensitive manufacturing processes, customer formulas, and FDA interaction records may be at risk of unauthorized disclosure. Given Catalent’s role as a contract manufacturer handling highly sensitive customer information across gene therapy and pharmaceutical manufacturing, these security incidents raise concerns about the adequacy of data protection measures.

Customer Concentration and Competitive Positioning Risks

The recent acquisition by Novo Holdings creates potential conflicts of interest and customer concentration risks that could impact Catalent’s competitive positioning. As a subsidiary of Novo Holdings, which has controlling interests in Novo Nordisk, Catalent may face customer concerns about confidentiality and competitive conflicts when serving companies that compete with Novo Nordisk products. The sale of three key fill-finish facilities to Novo Nordisk as part of the acquisition removes significant manufacturing capacity from Catalent’s available network and requires existing customers to find alternative suppliers for those facilities. Additionally, the company’s business model relies heavily on major pharmaceutical clients, with significant customer relationships including Bayer, Bristol-Myers Squibb, and Moderna, creating concentration risk if key accounts are lost due to competitive concerns or service delivery issues.

Sources

Save as PDF